{
    "clinical_study": {
        "@rank": "136113", 
        "acronym": "CBZF961X2201", 
        "arm_group": [
            {
                "arm_group_label": "BZF961", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the antiviral activity of 3 days of BZF961. To determine safety and tolerability\n      of BZF961 in HCV patients. To evaluate pharmacokinetics of BZF961 in HCV patients."
        }, 
        "brief_title": "Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent must be obtained before any assessment is performed Male &\n             female treatment naive subjects, age 18-60 years of age with Hepatitis C genotype-1.\n             Subjects must weight at least 50kg to participate in the study, and must have a body\n             mass index (BMI) within the range of 18-36 kg/m2 Able to communicate well with the\n             investigator, to understand and comply with the study requirements.\n\n        Exclusion Criteria:\n\n          -  Use of other investigational drugs at the time of enrollment, or within 30 days or 5\n             half-lives of enrollment, whichever is longer: or longer if required by local\n             regulations, and for any other limitation of participation in an investigational\n             trial based on local regulations.\n\n        Subjects that were previously treated for HCV infection."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01825980", 
            "org_study_id": "CBZF961X2201", 
            "secondary_id": "2012-003103-35"
        }, 
        "intervention": [
            {
                "arm_group_label": "BZF961", 
                "description": "There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.", 
                "intervention_name": "BZF961", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BZF961", 
                "description": "Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961", 
                "intervention_name": "Ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Ritonavir"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92120"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of 3 Days of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus (HCV) Infected Patients", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Viral load samples will be taken at Day 3.", 
            "measure": "HCV viral load", 
            "safety_issue": "Yes", 
            "time_frame": "Day 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01825980"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of participants with adverse events as a measure of safety", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Total BZF961 concentration in plasma", 
                "safety_issue": "Yes", 
                "time_frame": "Day 4"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}